“A working paper published Monday (PDF) claims that, despite the insistence of numerous U.S. officials, legalizing medical marijuana had no distinguishable effect on teen drug abuse rates in the surrounding communities.”

“A working paper published Monday (PDF) claims that, despite the insistence of numerous U.S. officials, legalizing medical marijuana had no distinguishable effect on teen drug abuse rates in the surrounding communities.”

“Marijuana and hydrocodone are two of the most widely used and abused drugs in the U.S. But according to a new study by one of the nation’s largest drug screening companies, chronic pain patients who are prescribed hydrocodone are less likely to take the painkiller if they are using marijuana.”
“A smokeless cannabis-vaporizing device delivers the same level of active therapeutic chemical and produces the same biological effect as smoking cannabis…
…smoked cannabis can alleviate the chronic pain caused by HIV-related neuropathy, but a concern was expressed that smoking cannabis was not safe. This study demonstrates an alternative method that gives patients the same effects and allows controlled dosing but without inhalation of the toxic products in smoke,” said study lead author Donald I. Abrams, MD, UCSF professor of clinical medicine.
…pills tend to provide patients with more THC than they need for optimal therapeutic effect and increase side effects.
Patients rated the “high” they experienced from both smoking and vaporization and there was no difference between the two methods by patient self-report of the effect, according to study findings. In addition, patients were asked which method they preferred.
“By a significant majority, patients preferred vaporization to smoking, choosing the route of delivery with the fewest side effects and greatest efficiency,” said Benowitz.”
Read more: http://www.sciencedaily.com/releases/2007/05/070515151145.htm

“The development of oral cancer is not a result of smoking cannabis per se; rather, it is hypothesized to be a result of contracting hpv through various forms of sharing and passing joints and other smoking apparatuses. Therefore, it is hypothesized that bogarting (and not passing) joints might decrease oral hpv among cannabis smokers.
It certainly may not be the cannabis smoke that causes oral cancers in heavy cannabis users. Most people who have ever smoked cannabis have most likely done so by sharing a rolled cigarette or pipe in a group setting. The sharing and passing of these smoking devices from an oral hpv-infected individual to an uninfected individual could easily provide a route of transmission for the virus between users. Frequency and setting should therefore be considered two major factors that might contribute to the likelihood of acquiring oral hpv.
Thus, the relationship between cannabis and various cancer types might not be from cannabis use itself, but rather from contracting high-risk types of oral hpv that lead to cancer in later life.”

“Oral cancer represents 3% of all cancers and its overall survival rate of 50% places it among the worst of all cancers
For many years cannabinoids have been used for medicinal and recreational purposes.
Recently, studies have focused on the therapeutic effects of cannabinoids on different cancers. The current study was the first to investigate the therapeutic effects of synthetic cannabinoids on oral cancer.
We investigated the effects of cannabinoid receptor agonists on (1) oral cancer cell viability in vitro and (2) oral cancer pain and tumor growth in a mouse cancer model.
Here we demonstrate the anti-nociceptive and anti-proliferative effects of systemic administration of cannabinoid receptor agonists on human oral cancer cells.
Our results suggest that systemic administration of cannabinoids decease oral cancer pain.
Our findings suggest a direct role for cannabinoid mechanisms in oral cancer pain and proliferation.
The systemic administration of cannabinoid receptor agonists may have important therapeutic implications wherein cannabinoid receptor agonists may reduce morbidity and mortality of oral cancer.
The present findings suggest that cannabinoid treatment may be a promising alternative therapy for oral cancer pain management. Furthermore, CBr2 agonism is not only palliative, but it may also be effective in inhibiting oral cancer growth, making the agonist a particularly desirable therapeutic agent.”
Full Text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099480/
“For the first time, a study has found that cannabis use may be associated with a decreased risk of bladder cancer, researchers reported at the American Urological Association 2013 annual meeting.
In a study of nearly 82,000 men, bladder cancer developed in 279 over an 11-year period. Subjects who smoked marijuana, but not tobacco, had a significant 45% decreased risk of bladder cancer compared with those who did not, after adjusting for age, body mass index, and race and ethnicity, according to lead investigator Anil A. Thomas, MD, a researcher with Southern California Permanent Medical Group in Los Angeles. Men who smoked tobacco, but not marijuana, had a significant 52% increased risk, a finding that is consistent with numerous previous studies. Men who smoked both had a 28% increased risk.
Of the 82,000 men, 41% reported ever using marijuana and 57% reported tobacco use; 27% reported used both tobacco and marijuana.”
http://www.renalandurologynews.com/bladder-cancer-risk-lower-in-pot-smokers/article/292174/#

“Regular cannabis smokers are no more likely to develop lung cancer than are people who indulge occasionally.
The finding of no significant increased risk held true whether the smokers imbibed once or twice – or more – each day, and regardless of how many years they had smoked, Dr. Li Rita Zhang reported at the annual meeting of the American Association of Cancer Research.
The study included data from six case-control studies conducted from 1999 to 2012 in the United States, Canada, the United Kingdom, and New Zealand, with a subject pool of 2,159 lung cancer cases and 2,985 controls. All of the studies were part of the International Lung Cancer Consortium (ILCCO), an international group of lung cancer researchers with the aim of sharing comparable data from ongoing and recently completed lung cancer studies from different geographical areas and ethnicities.
“OncologyPractice.com reports today that, “Regular cannabis smokers are no more likely to develop lung cancer than are people who indulge occasionally.” The cancer news site relates the findings of Dr. Li Rita Zhang reported at the annual meeting of the American Association of Cancer Research.”
““In an analysis of marijuana smokers that excluded tobacco smokers, there were no significant [cancer rate] differences in any of the comparisons, including habitual vs. nonhabitual use; number of joints smoked per day; duration of up to 20 years or duration of more than 20 years,” OncologyPractice reported.
The information fits in with prior assessments that marijuana smoking does not cause lung cancer.”
“In a recent presentation given at the annual meeting of the American Association of Cancer Research, investigators from the university of California, Los Angeles provided the latest data reaffirming that cannabis consumption is not associated with an elevated risk of lung cancer. Below is a summary of the findings from The Oncology Report:
The study included data from six case-control studies conducted from 1999 to 2012 in the United States, Canada, the United Kingdom, and New Zealand, with a subject pool of 2,159 lung cancer cases and 2,985 controls. All of the studies were part of the International Lung Cancer Consortium (ILCCO), an international group of lung cancer researchers with the aim of sharing comparable data from ongoing and recently completed lung cancer studies from different geographical areas and ethnicities.
Dr. Zhang of the University of California, Los Angeles, performed two analyses. One compared all lung cancer cases and all controls, regardless of concurrent or past tobacco use. Then, to reduce confounding by tobacco, she restricted the analysis to those who had never smoked tobacco.
… When compared with cannabis smokers who also used tobacco, habitual pot smokers had no significant increase in cancer risk. In an analysis of marijuana smokers that excluded tobacco smokers, there were no significant differences in any of the comparisons, including habitual vs. nonhabitual use; number of joints smoked per day; duration of up to 20 years or duration of more than 20 years.
The abstract of the presentation, which concludes “Our pooled results showed no significant association between the intensity, duration, or cumulative consumption of cannabis smoke and the risk of lung cancer overall or in never smokers,” is available online here.
Numerous preclinical studies have documented that cannabinoids possess potent anti-cancer properties, including the inhibition of lung cancer cell growth.”